Literature DB >> 23615762

Early cardiovascular remodelling in Fabry disease.

Luca Costanzo1, Sergio Buccheri, Piera Capranzano, Luigi Di Pino, Giuseppina Curatolo, Margherita Rodolico, Stefano Leggio, Anita Blundo, Corrado Tamburino, Ines Monte.   

Abstract

AIMS: Fabry disease (FD) is a rare X-linked genetic disorder caused by the deficiency or absent activity of lysosomal α-galactosidase A. Cardiovascular remodelling is a hallmark of FD. The present study aimed to comprehensively evaluate the cardiac, vascular and microvascular status in a population of patients with genetic mutations for FD without left ventricular hypertrophy (LVH). METHODS AND
RESULTS: This study includes subjects carrying genetic mutations for FD (Fabry disease mutation-carrier, FDMC) without LVH (n = 19). A group of control subjects (n = 19) matched for age, sex, body mass index and cardiovascular risk factors were also included. All subjects underwent echocardiography, carotid ultrasound scan, endothelial flow-mediated dilatation (FMD) and nailfold capillaroscopy (NFC) assessment. When compared to the subjects in the control group, FDMC patients showed significantly lower mean values of systolic myocardial velocity (7.33 ± 1.28 vs. 10.08 ± 1.63 cm/s, p < 0.0001), longitudinal systolic strain (-18.07 ± 1.72 vs. -21.15 ± 2.22%, p < 0.0001), significantly higher E/E' mean values (7.15 ± 1.54 vs. 5.98 ± 1.27, p = 0.016) and intima-media thickness mean values (0.80 ± 0.20 vs. 0.61 ± 0.19 mm, p = 0.005), significantly lower FMD (8.3 ± 4.6 vs. 12.2 ± 5.0%, p = 0.02), more atypical capillaries and irregular NFC architecture in FDMC than control subjects (52.6 vs. 0%, p < 0.0001; 78.9 vs. 36.8%, p = 0.02 respectively).
CONCLUSIONS: FD progressively involves cardiac, macrovascular and microvascular systems in an early stage. These features are present even in asymptomatic mutation carriers without LVH.

Entities:  

Mesh:

Year:  2013        PMID: 23615762     DOI: 10.1007/s10545-013-9607-1

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  28 in total

1.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

2.  Disease manifestations and X inactivation in heterozygous females with Fabry disease.

Authors:  Esther M Maier; Stephanie Osterrieder; Catharina Whybra; Markus Ries; Andreas Gal; Michael Beck; Adelbert A Roscher; Ania C Muntau
Journal:  Acta Paediatr Suppl       Date:  2006-04

3.  Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease.

Authors:  Frédéric Barbey; Noureddine Brakch; Ales Linhart; Xavier Jeanrenaud; Thomas Palecek; Jan Bultas; Michel Burnier; Daniel Hayoz
Journal:  Acta Paediatr Suppl       Date:  2006-04

4.  Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.

Authors:  José Zamorano; Viviana Serra; Leopoldo Pérez de Isla; Gisela Feltes; Andrea Calli; F Javier Barbado; Joan Torras; Salvador Hernandez; Julio Herrera; Jose A Herrero; Guillem Pintos
Journal:  Eur J Echocardiogr       Date:  2011-08-02

5.  Recommendations of the European Association of Echocardiography: how to use echo-Doppler in clinical trials: different modalities for different purposes.

Authors:  Maurizio Galderisi; Michael Y Henein; Jan D'hooge; Rosa Sicari; Luigi P Badano; Josè Luis Zamorano; Jos R T C Roelandt
Journal:  Eur J Echocardiogr       Date:  2011-05

6.  Early detection of Fabry cardiomyopathy by tissue Doppler imaging.

Authors:  Maurizio Pieroni; Cristina Chimenti; Roberta Ricci; Patrizio Sale; Matteo Antonio Russo; Andrea Frustaci
Journal:  Circulation       Date:  2003-03-31       Impact factor: 29.690

7.  Arterial remodelling in Fabry disease.

Authors:  P Boutouyrie; S Laurent; B Laloux; O Lidove; J P Grunfeld; D P Germain
Journal:  Acta Paediatr Suppl       Date:  2002

8.  Clinical usefulness of tissue Doppler imaging in predicting preclinical Fabry cardiomyopathy.

Authors:  Rocio Toro; Leopoldo Perez-Isla; Griselda Doxastaquis; Miguel A Barba; Alberto Rivera Gallego; Guillem Pintos; Francisco-Javier Barbados; Alipio Mangas; Jose L Zamorano
Journal:  Int J Cardiol       Date:  2008-08-08       Impact factor: 4.164

9.  Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease.

Authors:  Brigitte Stemper; Max J Hilz
Journal:  J Neurol       Date:  2003-08       Impact factor: 4.849

10.  Peripheral hemodynamics in patients with Fabry's disease.

Authors:  Y Seino; J K Vyden; M Philippart; H B Rose; K Nagasawa
Journal:  Am Heart J       Date:  1983-05       Impact factor: 4.749

View more
  3 in total

1.  Fabry's Disease: The Utility of a Multidisciplinary Screening Approach.

Authors:  Marco Angelo Monte; Massimiliano Veroux; Margherita Stefania Rodolico; Valentina Losi; Luigi Di Pino; Rita Bella; Giuseppe Lanza; Ines Paola Monte
Journal:  Life (Basel)       Date:  2022-04-22

2.  Prevalence of Raynaud phenomenon and nailfold capillaroscopic abnormalities in Fabry disease: a cross-sectional study.

Authors:  Samuel Deshayes; Laurent Auboire; Roland Jaussaud; Olivier Lidove; Jean-Jacques Parienti; Nathalie Triclin; Bernard Imbert; Boris Bienvenu; Achille Aouba
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

3.  Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment.

Authors:  Christoph Kampmann; Amandine Perrin; Michael Beck
Journal:  Orphanet J Rare Dis       Date:  2015-09-29       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.